Three dose regimens of adriamycin for induction of remission in acute leukemia in children: a Southwest Oncology Group Study.
Three therapeutic regimens (6-hr intervals for 6 doses daily for 3 days, and a single infusion) utilizing the same total dose of adriamycin for the induction of remission in children with late-stage acute leukemia were evaluated in 150 patients. Complete remission rates were 15%, 28%, and 25%, respectively. Twenty-five children who achieved complete bone marrow remissions with adriamycin therapy were treated a second time after subsequent relapses. Of these children 20% achieved second bone marrow remissions.
D000208:Acute Disease; D000293:Adolescent; D001853:Bone Marrow / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D007938:Leukemia / Q000188:drug therapy* / Q000401:mortality; D012075:Remission, Spontaneous
D004317:Doxorubicin